Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non–Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studie
The ODxT Test detected HER2 mutations in NSCLC with high analytical and clinical accuracy and identified HER2m populations with response rates similar to populations identified by CTAs, supporting clinical utility of the ODxT Test to inform treatment decisions for HER2m NSCLC.
Authors
- Maha Karnoub
- Kaline Pereira
- Shirin Khambata‐Ford
- Egbert F. Smit (ORCID: https://orcid.org/0000-0002-7329-6995)
- Anne Marie Velasco Roth
- Kōichi Goto (ORCID: https://orcid.org/0000-0002-3023-2510)
- Yasushi Goto
- Thomas J Ha
- Ryota Shiga
- Zhenhao Qi
- Adrianus J. de Langen (ORCID: https://orcid.org/0000-0001-7343-633X)
- Wenqin Feng
Institutions
- Leiden University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- Daiichi-Sankyo (Japan) (JP)
- Thermo Fisher Scientific (United States) (US)
- National Cancer Center Hospital East (JP)
- Daiichi Sankyo (United States) (US)
Publication Details
- Journal
- Archives of Pathology & Laboratory Medicine
- Published
- 2024-09-19
- DOI
- https://doi.org/10.5858/arpa.2024-0014-oa
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- AstraZeneca
- American Society of Clinical Oncology
- Daiichi-Sankyo
- Daiichi Sankyo Europe